Stock Track | Tandem Diabetes Care Soars 5.29% Intraday on Multiple Analyst Upgrades After Strong Quarterly Results

Stock Track
02/23

Tandem Diabetes Care's stock surged 5.29% during intraday trading on Monday, extending its positive momentum from the previous session.

The sharp rise follows the company's report of better-than-expected quarterly financial results, which has prompted a wave of positive reactions from Wall Street analysts.

Several firms raised their price targets on the stock, including Truist Securities (to $27 from $24), Barclays (to $56 from $55), and Goldman Sachs (to $28 from $25). Furthermore, Lake Street made a significant move by upgrading Tandem Diabetes Care to Buy from Hold and dramatically raising its price target to $50 from $14.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10